Clinical trials: PAR
Respiratory Syncytial Virus
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a…
- Trial name
- NCT01995175
- Testing
- Nasal swab sampling, Blood sampling, Diary cards
- Where
- 23 sites in United States, Argentina and 6 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of…
- Trial name
- NCT01287364
- Testing
- ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
- Where
- 6 sites in United States
- Volunteers
- 185 people
- Sponsor
- Sumitomo Pharma America, Inc.
Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to compare the effect of 6 weeks of treatment with beclomethasone dipropionate (BDP) nasal aerosol versus placebo on HPA-axis function, as assessed by 24-hour serum cortisol weighted mean, and to…
- Trial name
- NCT01697956
- Testing
- BDP
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Perennial Allergic Rhinitis
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
This is a 6 month, multicenter, randomized, open label, parallel group, study to evaluate the nasal safety of ciclesonide nasal aerosol and ciclesonide aqueous nasal spray administered once daily to male and female subjects 12…
- Trial name
- NCT01654536
- Testing
- ciclesonide nasal aerosol, ciclesonide nasal spray
- Where
- 31 sites in United States
- Volunteers
- 737 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus…
- Trial name
- NCT01401465
- Testing
- ciclesonide, mometasone
- Where
- 15 sites in United States
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis, PAR
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female…
- Trial name
- NCT01378429
- Testing
- ciclesonide nasal aerosol
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis, Allergic, Perennial
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
- Trial name
- NCT01134705
- Testing
- Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
- Where
- 35 sites in United States
- Volunteers
- 474 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol.
- Trial name
- NCT00988247
- Testing
- Beclomethasone dipropionate
- Where
- 34 sites in United States
- Volunteers
- 529 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial
A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis
The purpose of this study is to compare the effects (effectiveness and safety) of an intranasal corticosteroid (fluticasone furoate nasal spray [FFNS]), with a placebo nasal spray for the treatment of perennial (year-round)…
- Trial name
- NCT00609674
- Testing
- Fluticasone furoate nasal spray
- Where
- 37 sites in United States, Canada and 5 more
- Volunteers
- 315 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic…
- Trial name
- NCT01067105
- Testing
- ciclesonide HFA 160 μg
- Where
- 44 sites in United States
- Volunteers
- 824 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
- Trial name
- GSP 301-303 (NCT02709538)
- Testing
- GSP 301 NS
- Where
- 34 sites in United States
- Volunteers
- 601 people
- Sponsor
- Glenmark Specialty S.A.
Turner's Syndrome
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years.
- Trial name
- NCT01066052
- Testing
- r-hGH
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rhinitis, Allergic, Perennial
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray…
- Trial name
- NCT00449072
- Testing
- TAA-AQ, Nasacort® AQ, Claritin®
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Sanofi
Allergic Rhinitis, Perennial Allergic Rhinitis
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older…
- Trial name
- NCT00953147
- Testing
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg
- Where
- 45 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Sumitomo Pharma America, Inc.
Allergic Rhinitis
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).
- Trial name
- NCT01783548
- Testing
- BDP Nasal Aerosol
- Where
- 63 sites in United States
- Volunteers
- 547 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.